High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass by Grace M. Lee, Ian J. Welsby,

Slides:

Advertisements

Similar presentations

Increased peripheral platelet destruction and caspase-3– independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients by.

Advertisements

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser,

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

by Henrik Frederiksen, and Kai Schmidt

Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study by Lori-Ann Linkins,

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis.

Finding a diamond in the (mouse is) rough

Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants by Rachael P. Jackman, Xutao Deng, Douglas Bolgiano, Mila.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Tax fingerprint in adult T-cell leukemia

The effect of variation in donor platelet function on transfusion outcome: a semirandomized controlled trial by Anne M. Kelly, Stephen F. Garner, Theodora.

The Fanconi anemia cell line HSC536N is not sensitive to interferon-γ and does not cleave PARP in response to Fas-mediated cell killing by Tim R. Rutherford,

How I treat elderly patients with myeloma

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim.

David W. Barbara, MD, William J. Mauermann, MD, James R

Nonmyeloablative conditioning for relapsed follicular lymphoma

by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C

by Daniel W. Bougie, Ana I. Benito, Luis I

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

by Wolfram Springer, Alexander von Ruecker, and Roswitha Dickerhoff

by Jessica A. Reese, Xiaoning Li, Manfred Hauben, Richard H

How we choose factor VIII to treat hemophilia

by Alexander Röth, Andreas Hüttmann, Russell P

by Karl-Georg Fischer, Barbara Deschler, and Michael Lübbert

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,

by Robert McMillan, Jennifer Lopez-Dee, and Joseph C. Loftus

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

Lymphoma spread? Target CD47-SIRPα!

Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? by Marc Michel, Nichola Cooper, Christelle Jean, Christine Frissora, and.

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies by Grace M. Lee, Manali Joglekar, Maragatha Kuchibhatla, Sanjay Khandelwal,

Anti–protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis by Tamam Bakchoul, Heike Zöllner, Jean Amiral, Simon Panzer, Sixten.

Plasma biomarker concentrations between study groups.

Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery Barbara A Konkle, MD, Thomas L Bauer, MD, Gowthami.

Immunoblots of PLCβ isoforms in wild-type and PLCβ2/β3-null platelets.

by Wendy Lim, Sara K. Vesely, and James N. George

Overcoming “aspirin resistance” in MPN

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.

by Catherine Lai, Vishal Ranpura, Colin Wu, Matthew J. Olnes, Ankur R

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Heparin-induced thrombocytopenia

Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

How I treat heparin-induced thrombocytopenia and thrombosis

A binding relationship with thrombin

Full Uncapped Doses Of Chemotherapy In Non-Hodgkin's Lymphoma Patients With a High Body Surface Area Are Well Tolerated With No Increase In Toxicity, and.

Patient Tregs express normal levels of suppression.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Balancing bleeding in brain metastases

Cold agglutinin disease

Presentation transcript:

High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass by Grace M. Lee, Ian J. Welsby, Barbara Phillips-Bute, Thomas L. Ortel, and Gowthami M. Arepally Blood Volume 121(15): April 11, 2013 ©2013 by American Society of Hematology

Incidence of PRT/H Abs in healthy patients and patients undergoing CPB. (A) PRT/H antibody reactivity was measured by ELISA in healthy patients (Controls, n = 101) and patients after CPB (n = 500) at baseline, days 3 through 7, and day 30 after CPB. (B) Tim... Grace M. Lee et al. Blood 2013;121: ©2013 by American Society of Hematology

Serologic characteristics of PRT/H Abs. Grace M. Lee et al. Blood 2013;121: ©2013 by American Society of Hematology

PRT/H Abs activate platelets in a protamine-dependent manner. Grace M. Lee et al. Blood 2013;121: ©2013 by American Society of Hematology

Breakdown of seropositivity at d 30 for all CPB patients. Grace M. Lee et al. Blood 2013;121: ©2013 by American Society of Hematology

Correlation of PF4/H and PRT/H seropositivity. Grace M. Lee et al. Blood 2013;121: ©2013 by American Society of Hematology

PRT/H antibody cross-reactivity with NPH insulin. Grace M. Lee et al. Blood 2013;121: ©2013 by American Society of Hematology